Resources from the same session
LBA43 - Updated response data and analysis of progression free survival by mechanism of mismatch repair loss in endometrial cancer (EC) patients (pts) treated with pembrolizumab plus carboplatin/paclitaxel (CP) as compared to CP plus placebo (PBO) in the NRG GY018 trial
Presenter: Ramez Eskander
Session: Mini oral session - Gynaecological cancers
Resources:
Abstract
Slides
Webcast
740MO - Dostarlimab + chemotherapy for the treatment of primary advanced or recurrent endometrial cancer (pA/rEC): Analysis of progression free survival (PFS) and overall survival (OS) outcomes by molecular classification in the ENGOT-EN6-NSGO/GOG-3031/RUBY trial
Presenter: Mansoor Raza Mirza
Session: Mini oral session - Gynaecological cancers
Resources:
Abstract
Slides
Webcast
742MO - Neoadjuvant immune checkpoint blockade in mismatch repair deficient endometrial cancer
Presenter: Marco de Bruyn
Session: Mini oral session - Gynaecological cancers
Resources:
Abstract
Slides
Webcast
741MO - Luveltamab tazevibulin (STRO-002), an anti-folate receptor alpha (FolRα) antibody drug conjugate (ADC), demonstrates clinical activity in recurrent/progressive epithelial endometrial cancer (EEC): STRO-002-GM1 phase I dose expansion
Presenter: Bhavana Pothuri
Session: Mini oral session - Gynaecological cancers
Resources:
Abstract
Slides
Webcast
743MO - Efficacy and safety of QL1706 plus paclitaxel and cisplatin/carboplatin +/- bevacizumab (Bev) as 1L treatment in recurrent or metastatic cervical cancer (r/mCC): A single-arm, multicenter phase II study
Presenter: Danbo Wang
Session: Mini oral session - Gynaecological cancers
Resources:
Abstract
Slides
Webcast
744MO - AdvanTIG-202: Phase II randomized, multicenter, open-label study of tislelizumab (TIS) with or without ociperlimab (OCI) in patients (pts) with previously treated recurrent/metastatic (R/M) cervical cancer (CC)
Presenter: Jung-Yun Lee
Session: Mini oral session - Gynaecological cancers
Resources:
Abstract
Slides
Webcast
LBA44 - Camrelizumab plus famitinib versus camrelizumab alone and investigator’s choice of chemotherapy in women with recurrent or metastatic cervical cancer
Presenter: Xiaohua Wu
Session: Mini oral session - Gynaecological cancers
Resources:
Abstract
Slides
Webcast
Invited Discussant 743MO, 744MO and LBA44
Presenter: Alexandra Leary
Session: Mini oral session - Gynaecological cancers
Resources:
Slides
Webcast
LBA45 - Overall survival (OS) outcomes from NRG-GY004, a phase III study comparing single-agent olaparib or combination cediranib and olaparib to platinum (Plat) based chemotherapy in recurrent plat sensitive ovarian cancer (OvCa)
Presenter: Joyce Liu
Session: Mini oral session - Gynaecological cancers
Resources:
Abstract
Slides
Webcast
746MO - Randomized phase II trial of durvalumab in combination with olaparib and cediranib (DOC) compared to olaparib and cediranib (OC) or durvalumab and cediranib (DC) or standard of care chemotherapy (SOC) in platinum-resistant ovarian cancer with prior bevacizumab (NRG-GY023)
Presenter: Jung-Min Lee
Session: Mini oral session - Gynaecological cancers
Resources:
Abstract
Slides
Webcast